Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh.
King Fahd Medical Research Center, King Abdulaziz University, Saudi Arabia.
CNS Neurol Disord Drug Targets. 2023;22(1):2-5. doi: 10.2174/1871527321666220430142722.
G-protein-coupled receptors (GPCRs) are activated by manifold neurotransmitters, and their activation, in turn, evokes slow synaptic transmission. They are profoundly related to numerous psychiatric and neurological disorders such as schizophrenia and Parkinson's disease. The significant malady indications for GPCR modulators demonstrate a change towards obesity, diabetes, and Alzheimer's disease, while other central nervous system disorders persist highly represented. GPR52, GPR6, and GPR8 are recognised as orphan GPCRs, co-exist either with both the dopamine D2 and D1 receptors in neurons of the basal ganglia or with the dopamine D2 receptor alone, and recommend that between these orphan receptors, GPR52 has the maximum potential of being a therapeutic psychiatric receptor. Genetically modified creature models and molecular biological investigations have suggested that these improved GPCRs could be potential therapeutic psychiatric receptors. In this perspective, the role of molecular targets in GPCR-mediated signalling has been discussed that would be novel drug design and discovery options for a scientist to elaborate previous knowledge with modern techniques.
G 蛋白偶联受体 (GPCRs) 可被多种神经递质激活,其激活继而引发缓慢的突触传递。它们与许多精神和神经疾病密切相关,如精神分裂症和帕金森病。GPCR 调节剂的重要疾病适应症表明,肥胖症、糖尿病和阿尔茨海默病的治疗方向正在发生变化,而其他中枢神经系统疾病仍然高度存在。GPR52、GPR6 和 GPR8 被认为是孤儿 GPCR,它们要么与基底神经节神经元中的多巴胺 D2 和 D1 受体共存,要么单独与多巴胺 D2 受体共存,这表明在这些孤儿受体中,GPR52 最有可能成为治疗精神疾病的受体。基因修饰的动物模型和分子生物学研究表明,这些改良的 GPCR 可能是潜在的治疗精神疾病的受体。从这个角度来看,讨论了 GPCR 介导的信号转导中分子靶标的作用,这将为科学家提供新的药物设计和发现选择,以利用现代技术扩展以前的知识。